EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.66) by 1.52 percent. This is a 18.18 percent decrease over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $24.45 million which beat the analyst consensus estimate of $7.98 million by 206.54 percent. This is a 109.29 percent increase over sales of $11.68 million the same period last year.